BIOCON

Q1 FY27 Profit Surges 355% to ₹141 Crore on Robust Biosimilars Growth

Summary:

reported a strong Q1 FY27 performance, with consolidated net profit soaring 355% year-on-year to ₹141 crore, driven by healthy growth in its biosimilars and generics businesses, improved biopharma profitability, and lower finance costs. Revenue from operations increased 10% YoY to ₹4,336 crore, while EBITDA rose 7% to ₹902 crore. Biopharma revenue climbed 17% to ₹3,615 crore, supported by a 16% rise in biosimilars revenue to ₹2,855 crore and a 21% increase in generics revenue to ₹760 crore. Finance costs declined 23% YoY to ₹213 crore, reflecting debt reduction and balance sheet optimisation efforts, further boosting overall earnings. The company also expressed confidence in sustained long-term growth, supported by favourable biosimilars demand and expanded manufacturing capabilities in key global markets. Investment in securities market are subject to market risks. Read all the related documents carefully before investing,